Dementia-related psychosis readout could lead to label expansion for Acadia's Nuplazid
A new Phase III readout could speed Acadia's timeline to a potential regulatory submission of pimavanserin to treat dementia-related psychosis, an indication that afflicts a much larger population than the one for which the molecule is already approved as Nuplazid.
Acadia Therapeutics Inc. (NASDAQ:ACAD) climbed $15.05 (63%) to $38.85 on the news, adding more than $2.1 billion in market cap, on Monday after the company said it would stop early the Phase III HARMONY trial of pimavanserin to treat dementia-related psychosis based on interim data that met criteria requiring a one-sided p-value of less than 0.0033 on the study's primary endpoint, which measured time to relapse...
BCIQ Company Profiles